|
CH652145A5
(de)
|
1982-01-22 |
1985-10-31 |
Sandoz Ag |
Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
|
|
US4634666A
(en)
|
1984-01-06 |
1987-01-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Human-murine hybridoma fusion partner
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US4912094B1
(en)
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
DE69133566T2
(de)
|
1990-01-12 |
2007-12-06 |
Amgen Fremont Inc. |
Bildung von xenogenen Antikörpern
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1992003918A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5194594A
(en)
|
1990-09-07 |
1993-03-16 |
Techniclone, Inc. |
Modified antibodies
|
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Technology Ltd. |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
US5877218A
(en)
|
1994-01-10 |
1999-03-02 |
Teva Pharmaceutical Industries, Ltd. |
Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
DE19539493A1
(de)
|
1995-10-24 |
1997-04-30 |
Thomae Gmbh Dr K |
Starker homologer Promotor aus Hamster
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
WO1998040100A1
(en)
|
1997-03-10 |
1998-09-17 |
Ottawa Civic Loeb Research Institute |
USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
|
|
US5888809A
(en)
|
1997-05-01 |
1999-03-30 |
Icos Corporation |
Hamster EF-1α transcriptional regulatory DNA
|
|
CA2625839A1
(en)
|
1999-02-05 |
2000-08-10 |
Samsung Electronics Co., Ltd. |
Image texture retrieving method and apparatus thereof
|
|
IL166244A0
(en)
|
2001-07-12 |
2006-01-15 |
Jefferson Foote |
Super humanized antibodies
|
|
DE60235013D1
(de)
*
|
2001-07-25 |
2010-02-25 |
Facet Biotech Corp |
Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
|
|
EP1467756A4
(en)
|
2001-12-28 |
2007-03-21 |
Abgenix Inc |
METHODS OF USING ANTI-MUC18 ANTIBODIES
|
|
ES2307824T3
(es)
|
2001-12-28 |
2008-12-01 |
Amgen Fremont Inc. |
Uso de anticuerpos contra el antigeno muc18.
|
|
AU2002361886A1
(en)
|
2001-12-28 |
2003-07-24 |
Abgenix, Inc. |
Antibodies against the muc18 antigen
|
|
CN100522999C
(zh)
*
|
2002-02-14 |
2009-08-05 |
免疫医疗公司 |
抗cd20抗体及其融合蛋白和使用方法
|
|
EP1382615A1
(en)
*
|
2002-07-15 |
2004-01-21 |
Xerion Pharmaceuticals AG |
MCAM inhibitors
|
|
EP1567652B1
(de)
|
2002-11-29 |
2007-08-22 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG |
Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
|
|
DE10338531A1
(de)
|
2003-08-19 |
2005-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Reklonierung von Produktionszellen
|
|
EP2053408B1
(en)
*
|
2004-07-20 |
2012-03-07 |
Symphogen A/S |
A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
|
|
ATE433110T1
(de)
|
2004-11-10 |
2009-06-15 |
Boehringer Ingelheim Pharma |
Verwendung von durchflusszytometrischer analyse zur optimierung von zellbankingstrategien für cho-zellen
|
|
US20080124760A1
(en)
|
2006-07-26 |
2008-05-29 |
Barbara Enenkel |
Regulatory Nucleic Acid Elements
|
|
EP2609932B1
(en)
|
2006-12-01 |
2022-02-02 |
Seagen Inc. |
Variant target binding agents and uses thereof
|
|
DK2126093T3
(da)
|
2007-03-02 |
2013-01-07 |
Boehringer Ingelheim Pharma |
Forbedring af proteinfremstilling
|
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
|
EP2488201A4
(en)
*
|
2009-10-15 |
2013-12-25 |
Abbvie Inc |
IL-1 BINDING PROTEINS
|
|
AR079944A1
(es)
*
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
|
US8974782B2
(en)
*
|
2011-02-07 |
2015-03-10 |
Glaxo Group Limited |
Treatment of stroke comprising anti-MAG antibodies
|
|
EP2718327A1
(en)
*
|
2011-06-06 |
2014-04-16 |
Neotope Biosciences Limited |
Mcam antagonists and methods of treatment
|
|
EP2788024A1
(en)
*
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
|
TWI660972B
(zh)
*
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗ｍｃａｍ抗體及相關使用方法
|